Should You Buy NGM Biopharmaceuticals Inc (NGM) Stock on Monday?

Monday, September 18, 2023 02:00 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy NGM Biopharmaceuticals Inc (NGM) Stock on Monday?

Overall market sentiment has been down on NGM Biopharmaceuticals Inc (NGM) stock lately. NGM receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

NGM Biopharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on NGM!

See Full NGM Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With NGM Stock Today?

NGM Biopharmaceuticals Inc (NGM) stock is lower by -3.44% while the S&P 500 has gained 0.22% as of 1:58 PM on Monday, Sep 18. NGM has fallen -$0.04 from the previous closing price of $1.31 on volume of 129,239 shares. Over the past year the S&P 500 is higher by 14.36% while NGM has fallen -91.35%. NGM lost -$2.08 per share in the over the last 12 months.

More About NGM Biopharmaceuticals Inc

NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include NGM282 (aldafermin), NGM313 (MK-3655), NGM120, NGM120, NGM621, and NGM395, all these are focused on NASH, diabetes, oncology, AMD and metabolic disease. Click Here to get the full Stock Report for NGM Biopharmaceuticals Inc stock.